测量循环肿瘤细胞计数评估不明原发癌治疗效果的效用。
Utility of measuring circulating tumor cell counts to assess the efficacy of treatment for carcinomas of unknown primary origin.
机构信息
Department of Clinical Oncology, Graduate School of Medicine, Akita University, Akita, Japan.
Department of Clinical Pathology, Akita University Hospital, Akita, Japan.
出版信息
Anticancer Res. 2014 Jun;34(6):3165-8.
BACKGROUND/AIM: Carcinomas of unknown primary origin (CUPs) account for 3%-5% of all malignancies. The majority of CUPs have unfavorable prognosis and are chemoresistant. Predictive biomarkers should be established to improve therapeutic outcomes. Metastatic ability of CUPs may be related to the existence of circulating tumor cells (CTCs).
PATIENTS AND METHODS
Ten patients diagnosed with CUP visiting the Akita University Hospital participated in this study. CTCs were calculated by the CellSearch system.
RESULTS
The present observational study indicates that CTCs were detected in 50% of CUPs, and in 80% chemotherapeutically-naïve cases. Furthermore, decrease in CTC count between the pre-treatment and post-treatment phases were observed in chemosensitive cases.
CONCLUSION
Rapid assessment of the efficacy of chemotherapy by CTC count may become a useful predictive biomarker of CUPs.
背景/目的：不明原发灶癌（CUP）占所有恶性肿瘤的 3%-5%。大多数 CUP 预后不良且对化疗耐药。应建立预测生物标志物以改善治疗效果。CUP 的转移能力可能与循环肿瘤细胞（CTC）的存在有关。
患者和方法
本研究纳入了 10 名就诊于秋田大学医院的 CUP 患者。通过 CellSearch 系统计算 CTCs。
结果
本观察性研究表明，50%的 CUP 和 80%未经化疗的 CUP 中检测到 CTCs。此外，在化疗敏感病例中，治疗前后 CTC 计数减少。
结论
通过 CTC 计数快速评估化疗疗效可能成为 CUP 的有用预测生物标志物。
Zotero 插件